Literature DB >> 28502555

Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs.

Jacopo Giuliani1, Andrea Bonetti2.   

Abstract

Entities:  

Keywords:  Cost of drugs; ESMO-MCBS; Randomized phase 3 trials; Second-line therapy; Targeted therapies

Mesh：

Substances：

Year:  2017        PMID： 28502555     DOI： 10.1016/j.cllc.2017.04.007

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  2 in total

1.  Assessment of Financial Toxicity Among Patients With Advanced Lung Cancer in Western China.

Authors:  Tianqi Xu; Leidi Xu; Hangtian Xi; Yong Zhang; Ying Zhou; Ning Chang; Wenhui Yang; Yan Zhang; Ming Wang; Qing Ju; Xuemin Yang; Xiangxiang Chen; Yinggang Che; Fulin Chen; Shuoyao Qu; Jian Zhang
Journal:  Front Public Health       Date:  2022-01-12

2.  Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  Cancer Drug Resist       Date:  2021-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.